Compare Agilent Technologies Inc (A) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Agilent Technologies Inc trades at $149.12 (market cap $41.87B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.91. The key difference: Agilent Technologies Inc pays a 0.69% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| A | SJNK | |
|---|---|---|
Market Cap | $41.87B | — |
Sector | Health | Sector/Thematic |
52-Week High | $157.20 | $25.63 |
52-Week Low | $110.24 | $24.75 |
Enterprise Value | $43.42B | — |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $149.33, down 0.11% today, near its consensus price target of $156.73. The stock shows a bullish technical trend with strong moving averages, though RSI levels indicate overbought conditions. Fundamentally, the company maintains robust profitability with a 19.55% net income margin and 21.33% ROE, supported by consistent revenue around $6.9 billion in 2025. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The outlook remains positive with analyst consensus strongly favoring Buy ratings (77.5%), targeting modest upside. Key risks include valuation multiples above industry averages and dependence on biopharma spending. Earnings growth and strategic expansions in AI-driven diagnostics present opportunities, but investors should monitor competitive pressures and macroeconomic impacts on R&D budgets.
SJNK trades at $24.87, up 0.12% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The ETF shows consistent dividend payments, with recent distributions in mid-2026. Institutional activity includes notable position reductions by Cetera Investment Advisers and Balefire LLC in mid-2026, indicating some selling pressure.
The outlook remains cautious due to bearish technicals and institutional selling. Risks include high-yield bond sensitivity to interest rates and economic cycles. Opportunities lie in the ETF's monthly dividend stream, but investors should weigh credit risk and market volatility against income goals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
